Agenus reported 48% 3-year overall survival in its Phase 1b BOT+BAL study for recurrent ovarian cancer, unchanged from the 2-year estimate in a heavily pretreated group. Updated follow-up data were presented at IGC2026.
published
Agenus reported 48% 3-year overall survival in its Phase 1b BOT+BAL study for recurrent ovarian cancer, unchanged from the 2-year estimate in a heavily pretreated group. Updated follow-up data were presented at IGC2026.
Latest documented BWB result
BWB member result
Exit /ES with a huge win - 56 Points or 224 ticks
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.